Affimed Logo.jpg
Affimed Announces Acimtamig as International Nonproprietary Name for AFM13
09. November 2023 06:30 ET | Affimed N.V.
MANNHEIM, Germany, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate...
Affimed Logo.jpg
Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023
07. November 2023 06:30 ET | Affimed N.V.
MANNHEIM, Germany, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
Affimed Logo.jpg
Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
03. November 2023 12:05 ET | Affimed N.V.
Addition of Affimed’s innate cell engager (ICE®) improves cytotoxicity of natural killer (NK) cells and CAR-NK cellsNK cells with ICE® show at least comparable anti-tumor cell efficacy to CAR-NK cells...
Affimed Logo.jpg
Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting
02. November 2023 09:05 ET | Affimed N.V.
In 36 patients with CD30-positive lymphoma treated at the recommended Phase 2 dose level (RP2D), the combination treatment of AFM13 with allogeneic NK cells shows a 94.4% objective response rate and a...
Affimed Logo.jpg
Affimed to Participate in Upcoming Investor Conferences
01. November 2023 06:30 ET | Affimed N.V.
MANNHEIM, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate...
Affimed Logo.jpg
Affimed Announces Listing Transfer to Nasdaq Capital Markets
04. Oktober 2023 06:30 ET | Affimed N.V.
MANNHEIM, Germany, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed Logo.jpg
Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
27. September 2023 09:05 ET | Affimed N.V.
MANNHEIM, Germany, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed Logo.jpg
Affimed to Present at the Cantor Global Healthcare Conference 2023
21. September 2023 06:30 ET | Affimed N.V.
MANNHEIM, Germany, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed Logo.jpg
Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma
12. September 2023 06:30 ET | Affimed N.V.
AFM13 in combination with AlloNK® (also known as AB-101) will be investigated in the LuminICE-203 open-label, multi-center, multi-cohort, phase 2 study evaluating the efficacy and safety of the...
Affimed Logo.jpg
Affimed to Present at the H.C. Wainwright Annual Global Investment Conference
07. September 2023 06:30 ET | Affimed N.V.
HEIDELBERG, Germany, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...